The partners will work together to develop a breast cancer recurrence risk score using the company's technology.
The company intends to sell up to $75 million of its common stock for working capital and other purposes.
The firm also said that its HTG EdgeSeq technology has been adapted for use with the Qiagen GeneReader NGS System after technical feasibility testing.
The assay can be used to identify patients suitable for treatment with ALK-targeted therapeutics such as Pfizer's Xalkori.
The company had been warned by Nasdaq in August that it failed to comply with a minimum $10 million stockholder equity requirement to remain listed on the exchange.
The partners will offer pharmaceutical firms a complete next-generation sequencing-based solution for the development and commercialization of companion diagnostic tests.
The companies will initially focus on developing a companion diagnostic for Merck's investigational B cell lymphoma drug M7583.
The company said its HTG EdgeSeq system and EdgeSeq Diffuse Large B-Cell Lymphoma Cell of Origin Assay may now be distributed in the EU.